Head-to-head

BPC-157 vs TB-500

A field-by-field comparison of BPC-157 and TB-500 drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as recovery & repair compounds, so the useful question is how they differ within that category.

BPC-157 vs TB-500: editorial summary

BPC-157 and TB-500 are both associated with tissue-repair research, but they approach the biology differently. BPC-157 is a synthetic peptide fragment studied primarily in preclinical models of tendon, ligament, muscle and gastrointestinal repair. TB-500 is a synthetic fragment based on the actin-binding region of thymosin beta-4, with research focused more heavily on cell migration, wound closure and blood-vessel formation. Neither has the depth of controlled human evidence seen with approved medicines.

Key considerations

The clearest distinction is mechanism. BPC-157 is described in the PeptideIndex database in terms of nitric-oxide signalling, VEGFR2–Akt–eNOS signalling and effects on tendon fibroblasts. TB-500 is centred more directly on actin binding and cell migration, alongside angiogenic effects.
Their evidence limitations are also important. BPC-157's evidence is predominantly preclinical, while much of the human research associated with TB-500's parent molecule concerns full-length thymosin beta-4 rather than the TB-500 fragment itself. The two compounds therefore should not be treated as interchangeable simply because both appear in recovery discussions.

BPC-157 characteristics

BPC-157 is a 15-amino-acid synthetic fragment associated primarily with recovery and repair research. PeptideIndex rates its evidence as Emerging and notes that robust human trials for the commonly discussed tendon and soft-tissue applications are absent.

TB-500 characteristics

TB-500 is a 7-amino-acid fragment representing the actin-binding region of thymosin beta-4. PeptideIndex also rates it Emerging and notes that human evidence is limited, with much of the published biology concerning full-length thymosin beta-4 rather than TB-500 itself.

BPC-157 vs TB-500 at a glance

Attribute	BPC-157	TB-500
Category	Recovery & repair	Recovery & repair
Evidence grade	Emerging	Emerging
Also known as	Body Protection Compound 157, PL 14736	Thymosin Beta-4 fragment, TB4
Chain	15 amino acids (GEPPPGKPADDAGLV)	7 amino acids (actin-binding domain of Tβ4)
Mechanism	Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining.	Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines.
Reported benefits	Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain	Improved cell migration and wound closure in animal studies · Reported flexibility gains and reduced muscle spasm · Systemic action rather than site-specific, unlike BPC-157
Reported side effects	Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile	Fatigue or head-rush after dosing · Injection-site reaction · Theoretical tumour-growth concern given angiogenic activity
Half-life	Approximately 4 hours (stable oral form debated)	Roughly 2–3 hours, with tissue effects lasting far longer
Administration	Subcutaneous injection; oral capsules used for gut-specific goals	Subcutaneous or intramuscular injection
Dosing overview	Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks	Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose
Storage	Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days	Powder at room temperature short term; reconstituted 2–8 °C for up to 30 days
Legal status	Not FDA-approved. Research-chemical status in most countries; prohibited in sport.	Not approved for human use; sold for research purposes only.

Key differences between BPC-157 and TB-500

Both are recovery & repair compounds

BPC-157 and TB-500 are both indexed under recovery & repair, so they compete for the same use case rather than complementing each other. BPC-157: "A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints." TB-500: "A synthetic version of the active region of thymosin beta-4, a naturally occurring wound-healing protein present in nearly all human cells."

Mechanism of action

BPC-157: Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. TB-500: Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines.

Half-life and dosing frequency

BPC-157 is listed at approximately 4 hours (stable oral form debated); TB-500 at roughly 2–3 hours, with tissue effects lasting far longer. That difference is what drives the reported schedules: Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks versus Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose

Route of administration

BPC-157 is administered by subcutaneous injection; oral capsules used for gut-specific goals. TB-500 is administered by subcutaneous or intramuscular injection.

Legal and regulatory status differs

BPC-157: Not FDA-approved. Research-chemical status in most countries; prohibited in sport. TB-500: Not approved for human use; sold for research purposes only. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

BPC-157 is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c, used within ~30 days. TB-500 is stored powder at room temperature short term; reconstituted 2–8 °c for up to 30 days.

What BPC-157 and TB-500 have in common

Category: both listed as Recovery & repair
Evidence grade: both listed as Emerging

Each compound in brief

BPC-157

Recovery & repair · Emerging evidence

A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints.

Considerations: Nearly all evidence is preclinical (rodent); robust human trials are absent · Injected near the injury site is the common anecdotal practice, though systemic effects are proposed · Banned by WADA for competing athletes

TB-500

Recovery & repair · Emerging evidence

A synthetic version of the active region of thymosin beta-4, a naturally occurring wound-healing protein present in nearly all human cells.

Considerations: Frequently stacked with BPC-157 in anecdotal recovery protocols · Human data is limited to Tβ4 trials in dry-eye and cardiac injury · Prohibited by WADA at all times

Frequently asked questions

How do BPC-157 and TB-500 differ?

BPC-157 is primarily described through effects on tendon fibroblasts, nitric-oxide signalling and angiogenesis, while TB-500 is centred on actin binding, cell migration and angiogenesis. Their mechanisms overlap in some areas but are not identical.

Which has stronger human evidence?

Neither has strong human evidence for the commonly discussed recovery applications. BPC-157 is predominantly supported by preclinical research, while TB-500 has the additional complication that much published human research concerns full-length thymosin beta-4 rather than the TB-500 fragment itself.

Are BPC-157 and TB-500 the same compound?

No. BPC-157 is a 15-amino-acid fragment associated with gastric-derived protein research, whereas TB-500 is a 7-amino-acid fragment based on the actin-binding region of thymosin beta-4.